<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>VOLTAREN- diclofenac sodiumÂ gelÂ </strong><br>Clinical Solutions Wholesale<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use VoltarenÂ® Gel safely and effectively. See full prescribing information for VoltarenÂ® Gel.<br>Initial U.S. Approval: 1988</div>
<div></div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><p class="Highlighta">Total dose should not exceed 32 g per day, over all affected joints. (2.3) Voltaren Gel should be measured onto the enclosed dosing card to the appropriate 2 g or 4 g designation. (2)  (<a href="#section-2">2</a>)</p></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>Use during the peri-operative period in the setting of coronary artery bypass graft (CABG) surgery. (4)</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div>
<dl>
<dt>â€¢</dt>
<dd>Elevations of one or more liver tests may occur during therapy with diclofenac sodium.  These laboratory abnormalities may progress, may remain unchanged, or may be transient with continued therapy.  Borderline elevations (i.e. less than 3 times the ULN [ULN = the upper limit of normal range]) or greater elevations of transaminases occurred in about 15% of diclofenac-treated patients.  Of the markers of hepatic function, ALT (SGPT) is recommended for the monitoring of <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span>.  </dd>
<dt>Â </dt>
<dd>In clinical trials, meaningful elevations (i.e., more than 3 times the ULN) of AST (GOT) (ALT was not measured in all studies) occurred in about 2% of approximately 5,700 patients at some time during diclofenac treatment.  In a large, open-label, controlled trial of 3,700 patients treated for 2-6 months, patients were monitored first at 8 weeks and 1,200 patients were monitored again at 24 weeks.  Meaningful elevations of ALT and/orAST occurred in about 4% of patients and included marked elevations (i.e., more than 8 times the ULN) in about 1% of the 3,700 patients.  In that open-label study, a higher incidence of borderline (less than 3 times the ULN), moderate (3-8 times the ULN), and marked (&gt;8 times the ULN) elevations of ALT or AST was observed in patients receiving diclofenac when compared to other NSAIDs.  Elevations in transaminases were seen more frequently in patients with <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span> than in those with <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span>. </dd>
<dt>Â </dt>
<dd>Almost all meaningful elevations in transaminases were detected before patients became symptomatic.  Abnormal tests occurred during the first 2 months of therapy with diclofenac in 42 of the 51 patients in all trials who developed marked transaminase elevations.  </dd>
<dt>Â </dt>
<dd>In postmarketing reports, cases of drug-induced hepatotoxicity have been reported in the first month, and in some cases, the first 2 months of therapy, but can occur at any time during treatment with diclofenac.  Postmarketing surveillance has reported cases of severe hepatic reactions, including <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">liver necrosis</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, fulminant <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> with and without <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, and <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span>.  Some of these reported cases resulted in fatalities or liver transplantation. </dd>
<dt>Â </dt>
<dd>Physicians should measure transaminases periodically in patients receiving long-term therapy with diclofenac, because severe hepatotoxicity may develop without a prodrome of distinguishing symptoms.  The optimum times for making the first and subsequent transaminase measurements are not known.  Based on clinical trial data and postmarketing experiences, transaminases should be monitored within 4 to 8 weeks after initiating treatment with diclofenac.  However, severe hepatic reactions can occur at any time during treatment with diclofenac.  </dd>
<dt>Â </dt>
<dd>If abnormal liver tests persist or worsen, if clinical signs and/or symptoms consistent with liver disease develop, or if systemic manifestations occur (e.g., <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, dark urine, etc.), diclofenac sodium should be discontinued immediately.  To minimize the possibility that hepatic injury will become severe between transaminase measurements, physicians should inform patients of the warning signs and symptoms of hepatotoxicity (e.g., <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, right upper quadrant <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, and â€œflu-likeâ€? symptoms), and the appropriate action patients should take if these signs and symptoms appear.</dd>
<dt>Â </dt>
<dd>To minimize the potential risk for an adverse liver related event in patients treated with diclofenac sodium, the lowest effective dose should be used for the shortest duration possible.  Caution should be exercised in prescribing diclofenac sodium with concomitant drugs that are know to be potentially hepatotoxic (e.g., antibiotics, anti-epileptics).  (5.3)</dd>
</dl>
<dl>
<dt>â€¢</dt>
<dd>Long-term administration of NSAIDs has resulted in <span class="product-label-link" type="condition" conceptid="4152839" conceptname="Acute papillary necrosis">renal papillary necrosis</span> and other <span class="product-label-link" type="condition" conceptid="4220631" conceptname="Injury of kidney">renal injury</span>.Â Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role inÂ the maintenance of renal perfusion. In these patients, administration of an NSAID may cause a dose dependentÂ reduction in prostaglandin formation and, secondarily, in renal blood flow, which mayÂ precipitate overt renal decompensation. Patients at greatest risk of this reaction are those with impairedÂ renal function, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, liver dysfunction, those taking diuretics and ACE-inhibitors, and theÂ elderly. Discontinuation of NSAID therapy is usually followed by recovery to the pretreatment state. (5.6)</dd>
<dt>â€¢</dt>
<dd>As with other NSAIDs, <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> may occur in patients without prior exposure toÂ VoltarenÂ® Gel. VoltarenÂ® Gel should not be given to patients with the aspirin triad. This symptomÂ complex typically occurs in <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> patients who experience <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span> with or without <span class="product-label-link" type="condition" conceptid="253788" conceptname="Nasal polyp">nasal polyps</span>, orÂ who exhibit severe, potentially fatal <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> after taking aspirin or other NSAIDs <span class="Italics">[seeÂ Contraindications (4), Warnings and Precautions (5.7)]. </span>Emergency help should be sought in casesÂ where an <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reaction</span> occurs. (5.7)</dd>
</dl>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div><div></div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION, Medication Guide, and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 11/2013</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">WARNING: CARDIOVASCULAR AND GASTROINTESTINAL RISK</a></h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Dosing Card [See the Medication Guide â€“ Patient Instructions for Use]</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Lower extremities, including the knees, ankles, and feet</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Upper extremities including the elbows, wrists and hands</a></h2>
<h2><a href="#section-2.4" class="toc">2.4 Special Precautions</a></h2>
<h1><a href="#section-3" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-4" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-4.1" class="toc">5.1 Cardiovascular Thrombotic Events</a></h2>
<h2><a href="#section-4.2" class="toc">5.2 Gastrointestinal Effects â€“ Risk of GI Ulceration, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span>, and Perforation</a></h2>
<h2><a href="#section-4.3" class="toc">5.3 Hepatic Effects</a></h2>
<h2><a href="#section-4.4" class="toc">5.4 <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></a></h2>
<h2><a href="#section-4.5" class="toc">5.5 <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></a></h2>
<h2><a href="#section-4.6" class="toc">5.6 Renal Effects</a></h2>
<h2><a href="#section-4.7" class="toc">5.7 <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid Reactions</span></a></h2>
<h2><a href="#section-4.8" class="toc">5.8 <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">Skin Reactions</span></a></h2>
<h2><a href="#section-4.9" class="toc">5.9 Pregnancy</a></h2>
<h2><a href="#section-4.10" class="toc">5.10 Corticosteroid treatment</a></h2>
<h2><a href="#section-4.11" class="toc">5.11 <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">Inflammation</span></a></h2>
<h2><a href="#section-4.12" class="toc">5.12 Hematological Effects</a></h2>
<h2><a href="#section-4.13" class="toc">5.13 Preexisting <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span></a></h2>
<h2><a href="#section-4.14" class="toc">5.14 Sun Exposure</a></h2>
<h2><a href="#section-4.15" class="toc">5.15 Eye Exposure</a></h2>
<h2><a href="#section-4.16" class="toc">5.16 Laboratory Tests</a></h2>
<h1><a href="#section-5" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">6.1 Clinical Studies Experience</a></h2>
<h1><a href="#section-6" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">7.1 Aspirin</a></h2>
<h2><a href="#section-6.2" class="toc">7.2 Anticoagulants</a></h2>
<h2><a href="#section-6.3" class="toc">7.3 ACE-Inhibitors</a></h2>
<h2><a href="#section-6.4" class="toc">7.4 Diuretics</a></h2>
<h2><a href="#section-6.5" class="toc">7.5 Lithium</a></h2>
<h2><a href="#section-6.6" class="toc">7.6 Methotrexate</a></h2>
<h2><a href="#section-6.7" class="toc">7.7 Cyclosporine</a></h2>
<h2><a href="#section-6.8" class="toc">7.8 Oral Nonsteroidal Anti-inflammatory Drugs</a></h2>
<h2><a href="#section-6.9" class="toc">7.9 Topical Treatments</a></h2>
<h1><a href="#section-7" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-7.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-7.2" class="toc">8.2 Labor and Delivery</a></h2>
<h2><a href="#section-7.3" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-7.4" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-7.5" class="toc">8.5 Geriatric Use</a></h2>
<h1><a href="#section-8" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-9" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-10" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-10.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-10.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-10.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-11" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-12" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-12.1" class="toc">14.1 Pivotal Studies in <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">Osteoarthritis</span> of the Superficial Joints of the Extremities</a></h2>
<h1><a href="#section-13" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-14" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-14.1" class="toc">17.1 Medication Guide</a></h2>
<h2><a href="#section-14.2" class="toc">17.2 Cardiovascular effects</a></h2>
<h2><a href="#section-14.3" class="toc">17.3 Gastrointestinal effects</a></h2>
<h2><a href="#section-14.4" class="toc">17.4 Hepatotoxicity</a></h2>
<h2><a href="#section-14.5" class="toc">17.5 Adverse <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">Skin Reactions</span></a></h2>
<h2><a href="#section-14.6" class="toc">17.6 <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight gain</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span></a></h2>
<h2><a href="#section-14.7" class="toc">17.7 <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid reactions</span></a></h2>
<h2><a href="#section-14.8" class="toc">17.8 Effects during pregnancy</a></h2>
<h2><a href="#section-14.9" class="toc">17.9 Eye Exposure</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="id_9e499be3-8ee8-49ed-b96f-08f4c8e551d4"></a><a name="section-1"></a><p></p>
<h1>WARNING: CARDIOVASCULAR AND GASTROINTESTINAL RISK</h1>
<p class="First"><span class="Bold">Cardiovascular Risk</span></p>
<dl>
<dt>â€¢</dt>
<dd>
<span class="Bold">Nonsteroidal anti-inflammatory drugs (NSAIDs) may cause an increased risk of serious cardiovascular thrombotic events, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk <span class="Italics">[see Warnings and Precautions (5.1)]</span>.</span><br>
</dd>
<dt>â€¢</dt>
<dd><span class="Bold">VoltarenÂ® Gel is contraindicated for the treatment of peri-operative <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the setting of coronary artery bypass graft (CABG) surgery <span class="Italics">[see Contraindications (4)]</span>.</span></dd>
</dl>
<p><span class="Bold">Gastrointestinal Risk</span></p>
<dl>
<dt>â€¢</dt>
<dd><span class="Bold">NSAIDs cause an increased risk of serious gastrointestinal adverse events including <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal events <span class="Italics">[see Warnings and Precautions(5.2)].</span></span></dd>
</dl>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_96ad06c2-6ed0-4e8d-832d-bd1e8e16611a"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">VoltarenÂ® Gel is indicated for the relief of the <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> of <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span> of joints amenable to topical treatment,Â such as the knees and those of the hands.</p>
<dl>
<dt>â€¢</dt>
<dd>VoltarenÂ® Gel has not been evaluated for use on the spine, hip, or shoulder.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_ff400e4c-0755-4edf-b01e-5d55ce789d10"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b3c42efe-4b0c-4e52-bcc7-d0d9a7ee2c1d"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Dosing Card [See the Medication Guide â€“ Patient Instructions for Use]</h2>
<p class="First">The proper amount of VoltarenÂ® Gel should be measured using the dosing card supplied in the drug product carton. The dosing card is made of polypropylene, like the tube cap containing VoltarenÂ® Gel, but without the white colorant. The dosing card should be used for each application of drug product. The gel should be applied within the oblong area of the dosing card up to the 2 gram or 4 gram line (2 g for each elbow, wrist, or hand, and 4 g for each knee, ankle, or foot). The dosing card containing VoltarenÂ® Gel can be used to apply the gel. The hands should then be used to gently rub the gel into the skin. After using the dosing card, hold with fingertips, rinse, and dry. It treatment site is the hands, patients should wait at least one (1) hour to wash their hands</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3831254d-276d-45ab-ba0f-f7962860cd05"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Lower extremities, including the knees, ankles, and feet</h2>
<p class="First">Apply the gel (4 g) to the affected foot or knee or ankle, 4 times daily. VoltarenÂ® Gel should be gentlyÂ massaged into the skin ensuring application to the entire affected foot or knee or ankle. The entire footÂ includes the sole, top of the foot and the toes. Do not apply more than 16 g daily to any single joint ofÂ the lower extremities.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ee04c601-6936-412d-bf56-e3fcbe26d19c"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Upper extremities including the elbows, wrists and hands</h2>
<p class="First">Apply the gel (2 g) to the affected hand or elbow or wrist, 4 times daily. VoltarenÂ® Gel should be gentlyÂ massaged into the skin ensuring application to the entire affected hand or elbow or wrist. The entireÂ hand includes the palm, back of the hands, and the fingers. Do not apply more than 8 g daily to anyÂ single joint of the upper extremities.</p>
<p>Total dose should not exceed 32 g per day, over all affected joints.Â </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_cdc408e7-8790-4fd3-8fc0-05a5c8bb9a28"></a><a name="section-2.4"></a><p></p>
<h2>2.4 Special Precautions</h2>
<dl>
<dt>â€¢</dt>
<dd>Showering/bathing should be avoided for at least 1 hour after the application. Patient should washÂ his/her hands after use, unless the hands are the treated joint. If VoltarenÂ® Gel is applied to theÂ hand(s) for treatment; patient should not wash the treated hand(s) for at least 1 hour after theÂ application.<br>
</dd>
<dt>â€¢</dt>
<dd>VoltarenÂ® Gel should not be applied to open <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wounds</span>.<br>
</dd>
<dt>â€¢</dt>
<dd>Contact of VoltarenÂ® Gel with eyes and mucous membranes should be avoided.<br>
</dd>
<dt>â€¢</dt>
<dd>External heat and/or occlusive dressings should not be applied to treated joints.<br>
</dd>
<dt>â€¢</dt>
<dd>Exposure of the treated joint(s) to sunlight should be avoided.<br>
</dd>
<dt>â€¢</dt>
<dd>VoltarenÂ® Gel should not be used concomitantly with sunscreens, cosmetics, lotions, moisturizers,Â insect repellants, or other topical medications on the same skin sites has not been evaluated.<br>
</dd>
<dt>â€¢</dt>
<dd>Concomitant use of VoltarenÂ® Gel with oral non-steroidal anti-inflammatory drugsÂ (NSAIDs) has not been evaluated, and may increase adverse NSAIDs effects.Â <br>
</dd>
<dt>â€¢</dt>
<dd>Wearing of clothing or gloves should be avoided for at least 10 minutes after applying VoltarenÂ®Â Gel.</dd>
</dl>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_9007640d-0e8e-4d7d-bc2b-78825818283b"></a><a name="section-3"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">The use of VoltarenÂ® Gel is contraindicated in patients with a known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to diclofenac.</p>
<p>VoltarenÂ® Gel should not be administered in patients who have experienced <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, or otherÂ allergic-type reactions after taking aspirin or other NSAIDs. Severe, rarely fatal, anaphylactic-likeÂ reactions to NSAIDs have been reported in such patients <span class="Italics">[see Warnings and Precautions (5.1)].</span></p>
<p>VoltarenÂ® Gel is contraindicated in the setting of coronary artery bypass graft (CABG) surgery <span class="Italics">[seeÂ Warnings and Precautions (5.1</span>)<span class="Italics">]</span>.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_id_e1e0a576-4e0f-4910-9baf-2634bd70312d"></a><a name="section-4"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_49e09819-294d-49b1-9b14-b125f3d52e75"></a><a name="section-4.1"></a><p></p>
<h2>5.1 Cardiovascular Thrombotic Events</h2>
<p class="First">Clinical trials of several COX-2 selective and nonselective NSAIDs of up to three years duration haveÂ shown an increased risk of serious cardiovascular (CV) thrombotic events, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, andÂ <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, which can be fatal. All NSAIDs, both COX-2 selective and nonselective, may have a similarÂ risk. Patients with known CV disease or risk factors for CV disease may be at greater risk. To minimizeÂ the potential risk for an adverse CV event in patients treated with NSAIDs, the lowest effective doseÂ should be used for the shortest duration possible. Physicians and patients should remain alert for theÂ development of such events, even in the absence of previous CV symptoms. Patients should be informedÂ about the signs and/or symptoms of serious CV toxicity and the steps to take if they occur.</p>
<p>There is no consistent evidence that concurrent use of aspirin mitigates the increased risk of serious CVÂ thrombotic events associated with NSAIDs use. The concurrent use of aspirin and NSAIDs such asÂ diclofenac, does increase the risk of serious GI events <span class="Italics">[see Warnings and Precautions (5.2)].</span></p>
<p>Two large, controlled, clinical trials of a COX-2 selective NSAID for the treatment of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the firstÂ 10-14 days following CABG surgery found an increased incidence of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> and strokeÂ <span class="Italics">[see Contraindications (4)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a4102012-8aad-42f2-ae2b-d063bfad095a"></a><a name="section-4.2"></a><p></p>
<h2>5.2 Gastrointestinal Effects â€“ Risk of GI Ulceration, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span>, and Perforation</h2>
<p class="First">NSAIDs, including diclofenac, can cause serious gastrointestinal (GI) events including <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>,Â ulceration, and perforation of the stomach, small intestine or large intestine, which can be fatal. TheseÂ serious adverse events can occur at any time, with or without warning symptoms, in patients treated withÂ NSAIDs. Only one in five patients who develop a serious upper GI adverse event on NSAID therapy isÂ symptomatic. Upper GI <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span>, gross <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, or perforation caused by NSAIDs occur inÂ approximately 1% of patients treated for 3-6 months, and in about 2-4% of patients treated for one year.Â These trends continue with longer duration of use, increasing the likelihood of developing a serious GIÂ event at some time during the course of therapy. However, even short-term therapy is not without risk.</p>
<p>NSAIDs should be prescribed with extreme caution in patients with a prior history of <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> disease orÂ <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span>. Patients with a prior history of <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer disease</span> and/or gastrointestinalÂ <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> who use NSAIDs have a greater than 10-fold increased risk for developing a GI bleedÂ compared to patients with neither of these risk factors. Other factors that increase the risk of GI bleedingÂ in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longerÂ duration of NSAIDs therapy, smoking, use of alcohol, older age, and poor general health status. MostÂ spontaneous reports of fatal GI events are in elderly or debilitated patients and therefore special careÂ should be taken in treating this population.</p>
<p>To minimize the potential risk for an adverse GI event, the lowest effective dose should be used for theÂ shortest possible duration. Physicians and patients should remain alert for signs and symptoms of GIÂ ulceration and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> during diclofenac therapy and promptly initiate additional evaluation andÂ treatment if a serious GI adverse event is suspected. For high-risk patients, alternate therapies that do notÂ involve NSAIDs should be considered.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0a9173ed-25af-4d2b-82bb-261d39805daa"></a><a name="section-4.3"></a><p></p>
<h2>5.3 Hepatic Effects</h2>
<p class="First">Elevations of one or more liver tests may occur during therapy with diclofenac sodium.  These laboratory abnormalities may progress, may remain unchanged, or may be transient with continued therapy.  Borderline elevations (i.e. less than 3 times the ULN [ULN = the upper limit of normal range]) or greater elevations of transaminases occurred in about 15% of diclofenac-treated patients.  Of the markers of hepatic function, ALT (SGPT) is recommended for the monitoring of <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span>.  </p>
<p>In clinical trials, meaningful elevations (i.e., more than 3 times the ULN) of AST (GOT) (ALT was not measured in all studies) occurred in about 2% of approximately 5,700 patients at some time during diclofenac treatment.  In a large, open-label, controlled trial of 3,700 patients treated for 2-6 months, patients were monitored first at 8 weeks and 1,200 patients were monitored again at 24 weeks.  Meaningful elevations of ALT and/orAST occurred in about 4% of patients and included marked elevations (i.e., more than 8 times the ULN) in about 1% of the 3,700 patients.  In that open-label study, a higher incidence of borderline (less than 3 times the ULN), moderate (3-8 times the ULN), and marked (&gt;8 times the ULN) elevations of ALT or AST was observed in patients receiving diclofenac when compared to other NSAIDs.  Elevations in transaminases were seen more frequently in patients with <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span> than in those with <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span>.  </p>
<p>Almost all meaningful elevations in transaminases were detected before patients became symptomatic.  Abnormal tests occurred during the first 2 months of therapy with diclofenac in 42 of the 51 patients in all trials who developed marked transaminase elevations.  </p>
<p>In postmarketing reports, cases of drug-induced hepatotoxicity have been reported in the first month, and in some cases, the first 2 months of therapy, but can occur at any time during treatment with diclofenac.  Postmarketing surveillance has reported cases of severe hepatic reactions, including <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">liver necrosis</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, fulminant <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> with and without <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, and <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span>.  Some of these reported cases resulted in fatalities or liver transplantation.  </p>
<p>Physicians should measure transaminases periodically in patients receiving long-term therapy with diclofenac, because severe hepatotoxicity may develop without a prodrome of distinguishing symptoms.  The optimum times for making the first and subsequent transaminase measurements are not known.  Based on clinical trial data and postmarketing experiences, transaminases should be monitored within 4 to 8 weeks after initiating treatment with diclofenac.  However, severe hepatic reactions can occur at any time during treatment with diclofenac.  </p>
<p>If abnormal liver tests persist or worsen, if clinical signs and/or symptoms consistent with liver disease develop, or if systemic manifestations occur (e.g., <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, dark urine, etc.), diclofenac sodium should be discontinued immediately.  To minimize the possibility that hepatic injury will become severe between transaminase measurements, physicians should inform patients of the warning signs and symptoms of hepatotoxicity (e.g., <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, right upper quadrant <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, and â€œflu-likeâ€? symptoms), and the appropriate action patients should take if these signs and symptoms appear.</p>
<p>To minimize the potential risk for an adverse liver related event in patients treated with diclofenac sodium, the lowest effective dose should be used for the shortest duration possible.  Caution should be exercised in prescribing diclofenac sodium with concomitant drugs that are know to be potentially hepatotoxic (e.g., antibiotics, anti-epileptics).  </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_68f89947-6cce-42a2-8a95-c68923ec8c43"></a><a name="section-4.4"></a><p></p>
<h2>5.4 <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></h2>
<p class="First">NSAIDs, including VoltarenÂ® Gel, can lead to the onset of new <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> or worsening of preexistingÂ <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, either of which may contribute to the increased incidence of cardiovascularÂ events. Patients taking thiazides or loop diuretics may have impaired response to these therapies whenÂ taking NSAIDs. NSAIDs, including VoltarenÂ® Gel should be used with caution in patients withÂ <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. Blood pressure should be monitored closely during the initiation of therapy withÂ VoltarenÂ® Gel and throughout the course of therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b37dbc80-282c-4f05-a3c5-fa0c5009ddfa"></a><a name="section-4.5"></a><p></p>
<h2>5.5 <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid retention</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> have been observed in some patients treated with NSAIDs, includingÂ VoltarenÂ® Gel. VoltarenÂ® Gel should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span> or heartÂ failure.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f1ee462e-6625-4c06-891c-7be01a1f0393"></a><a name="section-4.6"></a><p></p>
<h2>5.6 Renal Effects</h2>
<p class="First">Long-term administration of NSAIDs has resulted in <span class="product-label-link" type="condition" conceptid="4152839" conceptname="Acute papillary necrosis">renal papillary necrosis</span> and other <span class="product-label-link" type="condition" conceptid="4220631" conceptname="Injury of kidney">renal injury</span>.Â Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role inÂ the maintenance of renal perfusion. In these patients, administration of an NSAID may cause a dose-dependentÂ reduction in prostaglandin formation and, secondarily, in renal blood flow, which mayÂ precipitate overt renal decompensation. Patients at greatest risk of this reaction are those with impairedÂ renal function, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, liver dysfunction, those taking diuretics and ACE-inhibitors, and theÂ elderly. Discontinuation of NSAID therapy is usually followed by recovery to the pretreatment state.</p>
<p>No information is available from controlled clinical studies regarding the use of VoltarenÂ® Gel inÂ patients with advanced <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>. Therefore, treatment with VoltarenÂ® Gel is not recommended inÂ patients with advanced <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>. If VoltarenÂ® Gel therapy is initiated, close monitoring of theÂ patient's renal function is advisable.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7ad48f2e-1ce4-4b56-8ba1-7c55afcb24dd"></a><a name="section-4.7"></a><p></p>
<h2>5.7 <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid Reactions</span></h2>
<p class="First">As with other NSAIDs, <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> may occur in patients without prior exposure toÂ VoltarenÂ® Gel. VoltarenÂ® Gel should not be given to patients with the aspirin triad. This symptomÂ complex typically occurs in <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> patients who experience <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span> with or without <span class="product-label-link" type="condition" conceptid="253788" conceptname="Nasal polyp">nasal polyps</span>, orÂ who exhibit severe, potentially fatal <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> after taking aspirin or other NSAIDs <span class="Italics">[seeÂ Contraindications (4), Warnings and Precautions (5.7)]. </span>Emergency help should be sought in casesÂ where an <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reaction</span> occurs.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_98b6da27-fbd7-49e3-9270-daa411ed343c"></a><a name="section-4.8"></a><p></p>
<h2>5.8 <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">Skin Reactions</span></h2>
<p class="First">NSAIDs, including VoltarenÂ® Gel, can cause serious skin adverse events such as <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>,Â <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson Syndrome</span> (SJS), and <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span> (TEN), which can be fatal. TheseÂ serious events may occur without warning. Patients should be informed about the signs and symptomsÂ of serious skin manifestations, and the use of the drug should be discontinued at the first appearance ofÂ <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> or any other signs of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>.</p>
<p>VoltarenÂ® Gel should not be applied to open skin <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wounds</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammations</span>, or exfoliativeÂ <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>, as it may affect absorption and tolerability of the drug. VoltarenÂ® Gel should not be allowedÂ to come into contact with the eyes or with mucous membranes.</p>
<p>The effect of VoltarenÂ® Gel under occlusive dressings has not been evaluated, and should be avoided.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_pregnancy_duplicate_id_97075c3c-776c-4b20-a05f-65d83c7d060f"></a><a name="section-4.9"></a><p></p>
<h2>5.9 Pregnancy</h2>
<p class="First">As with other NSAIDs, VoltarenÂ® Gel should be avoided in late pregnancy, because it may causeÂ premature closure of the ductus arteriosus.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7428645c-e0eb-41a1-a589-c2e5cfb79b74"></a><a name="section-4.10"></a><p></p>
<h2>5.10 Corticosteroid treatment</h2>
<p class="First">VoltarenÂ® Gel cannot be expected to substitute for corticosteroids or to treat corticosteroidÂ insufficiency. Abrupt discontinuation of corticosteroids may lead to exacerbation of corticosteroid-responsiveÂ illness. Patients on prolonged corticosteroid therapy should have their therapy tapered slowlyÂ if a decision is made to discontinue corticosteroids.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c4a26d6d-1289-48c8-a51f-3282b1759948"></a><a name="section-4.11"></a><p></p>
<h2>5.11 <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">Inflammation</span></h2>
<p class="First">The pharmacological activity of diclofenac in reducing <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>, and possibly <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, may diminishÂ the utility of these diagnostic signs in detecting infectious complications of presumed noninfectious,Â painful conditions.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_eb3f349f-a22c-4302-b87c-31f200a93236"></a><a name="section-4.12"></a><p></p>
<h2>5.12 Hematological Effects</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span> is sometimes seen in patients receiving NSAIDs. This may be due to <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>, occult orÂ gross GI blood loss, or an incompletely described effect upon erythropoeisis. Patients on long-termÂ treatment with NSAIDs, including VoltarenÂ® Gel, should have their hemoglobin or hematocrit checkedÂ if they exhibit any signs or symptoms of <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> or blood loss.</p>
<p>NSAIDs inhibit platelet aggregation and have been shown to prolong <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">bleeding time</span> in some patients.Â Unlike aspirin, their effect on platelet function is quantitatively less, of shorter duration, and reversible.Â Patients treated with VoltarenÂ® Gel who may be adversely affected by alteration in platelet function,Â such as those with <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">coagulation disorders</span> or patients receiving anticoagulants should be carefullyÂ monitored.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b9ed9219-c4fd-45a3-a063-2ab4ffb72b93"></a><a name="section-4.13"></a><p></p>
<h2>5.13 Preexisting <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span></h2>
<p class="First">Patients with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> may have aspirin-sensitive <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>. The use of aspirin in patients with aspirin sensitiveÂ <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> has been associated with severe <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, which can be fatal. Since crossÂ reactivity, including <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, between aspirin and other nonsteroidal anti-inflammatory drugs hasÂ been reported in such aspirin-sensitive patients, VoltarenÂ® Gel should not be administered to patientsÂ with this form of aspirin sensitivity and should be used with caution in patients with preexisting <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e2611104-d82d-42e7-b813-586c4dbff5ed"></a><a name="section-4.14"></a><p></p>
<h2>5.14 Sun Exposure</h2>
<p class="First">Patients should minimize or avoid exposure to natural or artificial sunlight on treated areas becauseÂ studies in animals indicated topical diclofenac treatment resulted in an earlier onset of ultraviolet light inducedÂ <span class="product-label-link" type="condition" conceptid="135777" conceptname="Neoplasm of uncertain behavior of skin">skin tumors</span>. The potential effects of VoltarenÂ® Gel on skin response to ultraviolet damage inÂ humans are not known.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ba878a7f-5624-4411-be01-2f9fbe18d0dc"></a><a name="section-4.15"></a><p></p>
<h2>5.15 Eye Exposure</h2>
<p class="First">Contact of VoltarenÂ® Gel with eyes and mucosa, although not studied, should be avoided. PatientsÂ should be advised that if eye contact occurs, they should immediately wash out the eye with water orÂ saline and consult a physician if irritation persists for more than an hour.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="i4i_lab_tests_id_4410d14d-7d2f-49ca-b0a6-a6c0c0fed1dc"></a><a name="section-4.16"></a><p></p>
<h2>5.16 Laboratory Tests</h2>
<p class="First">Because serious GI tract ulcerations and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> can occur without warning symptoms, physiciansÂ should monitor for signs or symptoms of GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. Patients on long-term treatment with NSAIDs,Â should have a CBC and a chemistry profile checked periodically. If abnormal liver tests or renal testsÂ persist or worsen, VoltarenÂ® Gel should be discontinued.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_1f7f34c0-f816-4cee-972c-db1ff84fc445"></a><a name="section-5"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_07edaec4-a76f-4f1e-8ac2-5303a09bdf8e"></a><a name="section-5.1"></a><p></p>
<h2>6.1 Clinical Studies Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed inÂ the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drugÂ and may not reflect the rates observed in practice.</p>
<p>During clinical development, 913 patients were exposed to VoltarenÂ® Gel in randomized, double-blind,Â multicenter, vehicle-controlled, parallel-group studies in <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span> of the superficial joints of theÂ extremities. Of these, 513 patients received VoltarenÂ® Gel for <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span> of the knee and 400 wereÂ treated for <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span> of the hand. Additionally, 583 patients were exposed to VoltarenÂ® Gel in anÂ uncontrolled, open-label, long-term safety trial in <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span> of the knee. Of these, 355 patients wereÂ treated for <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span> of 1 knee and 228 were treated for <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span> of both knees. Duration ofÂ exposure ranged from 8 to 12 weeks for the placebo-controlled studies, and up to 12 months for theÂ open-label safety trial.</p>
<p><span class="Italics"><span class="Underline">Short-Term Placebo-Controlled Trials:</span></span></p>
<p><span class="Italics">Adverse reactions observed in at least 1% of patients treated with VoltarenÂ® Gel:</span></p>
<p>Non-serious adverse reactions that were reported during the short-term placebo-controlled studiesÂ comparing VoltarenÂ® Gel and placebo (vehicle gel) over study periods of 8 to 12 weeks (16 g per day),Â were <span class="product-label-link" type="condition" conceptid="4319310" conceptname="Application site reaction">application site reactions</span>. These were the only adverse reactions that occurred in &gt; 1% of treatedÂ patients with a greater frequency in the VoltarenÂ® Gel group (7%) than the placebo group (2%).Â </p>
<p>Table 1 lists the types of <span class="product-label-link" type="condition" conceptid="4319310" conceptname="Application site reaction">application site reactions</span> reported. <span class="product-label-link" type="condition" conceptid="4319313" conceptname="Application site rash">Application site dermatitis</span> was the mostÂ frequent type of <span class="product-label-link" type="condition" conceptid="4319310" conceptname="Application site reaction">application site reaction</span> and was reported by 4% of patients treated with VoltarenÂ® Gel,Â compared to 1% of placebo patients.</p>
<a name="_Refid_4fdfb671-7c49-4675-802b-5d28aa373"></a><table>
<caption><span>Table 1: Non-serious Application Site Adverse Reactions (â‰¥ 1% Voltaren<span class="Sup">Â®</span>Â Gel Patients) â€“ Short-term Controlled Trials</span></caption>
<col width="45%">
<col width="25%">
<col width="30%">
<tbody class="Headless">
<tr class="First">
<td class="Rrule Toprule" valign="top"><p class="First"><span class="Bold">Adverse Reaction<span class="Sup">â€ </span></span></p></td>
<td class="Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Voltaren<span class="Sup">Â®</span>Â Gel</span><br><span class="Bold">N = 913</span></p></td>
<td class="Toprule" align="center" valign="top"><p class="First"><span class="Bold">Placebo (vehicle)</span><br><span class="Bold">N = 876</span></p></td>
</tr>
<tr>
<td class="Rrule" valign="top"></td>
<td class="Rrule" align="center" valign="top"><p class="First">N (%)</p></td>
<td align="center" valign="top"><p class="First">N (%)</p></td>
</tr>
<tr>
<td class="Rrule" valign="top"><p class="First"><span class="Italics">Any <span class="product-label-link" type="condition" conceptid="4319310" conceptname="Application site reaction">application site reaction</span></span></p></td>
<td class="Rrule" align="center" valign="top"><p class="First"><span class="Italics">62 (7)</span></p></td>
<td align="center" valign="top"><p class="First"><span class="Italics">19 (2)</span></p></td>
</tr>
<tr>
<td class="Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4319313" conceptname="Application site rash">Application site dermatitis</span></p></td>
<td class="Rrule" align="center" valign="top"><p class="First">32 (4)</p></td>
<td align="center" valign="top"><p class="First">6 (&lt;1)</p></td>
</tr>
<tr>
<td class="Rrule" valign="top"><p class="First">Application site <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span></p></td>
<td class="Rrule" align="center" valign="top"><p class="First">7 (&lt;1)</p></td>
<td align="center" valign="top"><p class="First">1 (&lt;1)</p></td>
</tr>
<tr>
<td class="Rrule" valign="top"><p class="First">Application site <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span></p></td>
<td class="Rrule" align="center" valign="top"><p class="First">6 (&lt;1)</p></td>
<td align="center" valign="top"><p class="First">3 (&lt;1)</p></td>
</tr>
<tr>
<td class="Rrule" valign="top"><p class="First">Application site <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span></p></td>
<td class="Rrule" align="center" valign="top"><p class="First">5 (&lt;1)</p></td>
<td align="center" valign="top"><p class="First">3 (&lt;1)</p></td>
</tr>
<tr>
<td class="Rrule" valign="top"><p class="First">Application site dryness</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">4 (&lt;1)</p></td>
<td align="center" valign="top"><p class="First">3 (&lt;1)</p></td>
</tr>
<tr>
<td class="Rrule" valign="top"><p class="First">Application site <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">vesicles</span></p></td>
<td class="Rrule" align="center" valign="top"><p class="First">3 (&lt;1)</p></td>
<td align="center" valign="top"><p class="First">0 </p></td>
</tr>
<tr>
<td class="Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4318383" conceptname="Application site irritation">Application site irritation</span> </p></td>
<td class="Rrule" align="center" valign="top"><p class="First">2 (&lt;1)</p></td>
<td align="center" valign="top"><p class="First">0 </p></td>
</tr>
<tr class="Last">
<td class="Botrule Rrule" valign="top"><p class="First">Application site <span class="product-label-link" type="condition" conceptid="4105835" conceptname="Papule">papules</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">1 (&lt;1)</p></td>
<td class="Botrule" align="center" valign="top"><p class="First">0 </p></td>
</tr>
</tbody>
</table>
<p><span class="Bold"><span class="Sup">â€ </span></span>Preferred Term according to MedDRA 9.1.</p>
<p>In the placebo-controlled trials, the discontinuation rate due to adverse reactions was 5% for patientsÂ treated with VoltarenÂ® Gel, and 3% for patients in the placebo group. <span class="product-label-link" type="condition" conceptid="4319310" conceptname="Application site reaction">Application site reactions</span>,Â including <span class="product-label-link" type="condition" conceptid="4319313" conceptname="Application site rash">application site dermatitis</span>, were the most frequent reason for treatment discontinuation.Â </p>
<p><span class="Italics"><span class="Underline">Long-term Open-label Safety Trial:</span></span></p>
<p>In the open-label, long-term safety study, distribution of adverse reactions was similar to that in theÂ placebo-controlled studies. In this study, where patients were treated for up to 1 year with VoltarenÂ® GelÂ up to 32 g per day, <span class="product-label-link" type="condition" conceptid="4319313" conceptname="Application site rash">application site dermatitis</span> was observed in 11% of patients. Adverse reactions thatÂ led to the discontinuation of the study drug were experienced in 12% of patients. The most commonÂ adverse reaction that led to discontinuation of the study was <span class="product-label-link" type="condition" conceptid="4319313" conceptname="Application site rash">application site dermatitis</span>, which wasÂ experienced by 6% of patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_5eff9203-05e7-43ce-a6ec-9035a133d5a3"></a><a name="section-6"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First">Â Â Â </p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e2234142-54fb-4177-9378-032948bcb783"></a><a name="section-6.1"></a><p></p>
<h2>7.1 Aspirin</h2>
<p class="First">When diclofenac is administered with aspirin, the binding of diclofenac to protein is reduced, althoughÂ the clearance of free diclofenac is not altered. The clinical significance of this interaction is not known;Â however, as with other NSAIDs, concomitant administration of diclofenac and aspirin is not generallyÂ recommended because of the potential of increased adverse effects.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8ac73136-afe4-47e3-ad8d-38c5f1d905ac"></a><a name="section-6.2"></a><p></p>
<h2>7.2 Anticoagulants</h2>
<p class="First">The effects of anticoagulants such as warfarin and NSAIDs on GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> are synergistic, such thatÂ users of both drugs together have a risk of serious GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> higher than users of either drug alone.Â </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3106cb1e-5b6d-46f9-ae6e-3b95764b573b"></a><a name="section-6.3"></a><p></p>
<h2>7.3 ACE-Inhibitors</h2>
<p class="First">NSAIDs may diminish the antihypertensive effect of angiotensin converting enzyme (ACE) inhibitors.Â This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE-inhibitors.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c59fcf58-1240-4469-b855-21527dcc3c5e"></a><a name="section-6.4"></a><p></p>
<h2>7.4 Diuretics</h2>
<p class="First">Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce theÂ natriuretic effect of furosemide and thiazides in some patients. The response has been attributed toÂ inhibition of renal prostaglandin synthesis. During concomitant therapy with NSAIDs, the patientÂ should be observed closely for signs of <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> <span class="Italics">[see Warnings and Precautions (5.6)]</span>, as well as toÂ assure diuretic efficacy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_966510fe-dc50-43c4-86ab-4eab1aae5046"></a><a name="section-6.5"></a><p></p>
<h2>7.5 Lithium</h2>
<p class="First">NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance.Â The mean minimum lithium concentration increased 15% and the renal clearance was decreased byÂ approximately 20%. These effects have been attributed to inhibition of renal prostaglandin synthesis byÂ the NSAID. Thus, when NSAIDs, including diclofenac, and lithium are administered concurrently,Â patients should be observed carefully for signs of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium toxicity</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ffacd227-3325-4eb0-b791-3509e2a70245"></a><a name="section-6.6"></a><p></p>
<h2>7.6 Methotrexate</h2>
<p class="First">NSAIDs have been reported to competitively inhibit methotrexate accumulation in rabbit kidney slices.Â This may indicate that they could enhance the toxicity of methotrexate. Caution should be used whenÂ NSAIDs, including diclofenac, are administered concomitantly with methotrexate.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f9e4a98f-c05f-421c-b348-017485eee585"></a><a name="section-6.7"></a><p></p>
<h2>7.7 Cyclosporine</h2>
<p class="First">Diclofenac, like other NSAIDs, may affect renal prostaglandins and increase the toxicity of certainÂ drugs. Therefore concomitant therapy with diclofenac may increase cyclosporineâ€™s <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span>.Â Caution should be used when diclofenac is administered concomitantly with cyclosporine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b5df0bcd-eb4a-4e5b-9e31-a66e266d6c69"></a><a name="section-6.8"></a><p></p>
<h2>7.8 Oral Nonsteroidal Anti-inflammatory Drugs</h2>
<p class="First">Specific interaction studies of VoltarenÂ® Gel and oral NSAIDs were not performed. Also, the clinicalÂ trials of VoltarenÂ® Gel prohibited concomitant use of oral NSAIDS. There is systemic exposure toÂ diclofenac following normal use of VoltarenÂ® Gel, up to 6% of the systemic levels of a single oral doseÂ of diclofenac sodium. <span class="Italics">[see Clinical Pharmacology (12.3)] </span>Therefore, concomitant administration ofÂ VoltarenÂ® Gel with oral NSAIDs or aspirin may result in increased adverse NSAID effects.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0b9664e4-82f2-45d2-90b5-c07f4de4cacc"></a><a name="section-6.9"></a><p></p>
<h2>7.9 Topical Treatments</h2>
<p class="First">Concomitant use of VoltarenÂ® Gel with other topical products, including topical medications,Â sunscreens, lotions, moisturizers, and cosmetics, on the same skin site has not been tested and should beÂ avoided because of the potential to alter local tolerability and absorption.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="i4i_specific_populations_id_f7edbf10-9cce-40a6-95eb-2c9a5c09f811"></a><a name="section-7"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_326a1e4d-7236-43ad-9658-b0fa98d87004"></a><a name="section-7.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First">The safety of VoltarenÂ® Gel has not been established during pregnancy. There are no well-controlledÂ studies of diclofenac in pregnant women. Human and animal studies indicate that diclofenac crosses theÂ placenta. In late pregnancy, as with other NSAIDs, VoltarenÂ® Gel should be avoided because it mayÂ cause premature closure of the ductus arteriosus.</p>
<p><span class="Italics">Teratogenic effects</span></p>
<p>Pregnancy Category C: Studies in mice, rats, and rabbits in which diclofenac was administered orallyÂ throughout gestation revealed no evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> despite the induction of maternal toxicityÂ and fetal toxicity corresponding to a human equivalent dose approximately 4.5-, 2-, and 9-fold (mouse,Â rat, rabbit, respectively) of the maximum human topical dose of VoltarenÂ® Gel (based on bioavailabilityÂ and body surface area comparison).</p>
<p><span class="Italics">Nonteratogenic effects</span></p>
<p>The use of diclofenac, as with other NSAIDs, is associated with the adverse fetal cardiovascular effectÂ of premature closure of the ductus arteriosus.</p>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="i4i_labour_delivery_id_737a4f63-5266-477c-b94e-faeb41ec7d32"></a><a name="section-7.2"></a><p></p>
<h2>8.2 Labor and Delivery</h2>
<p class="First">In rat studies with oral NSAIDs, including diclofenac, as with other drugs known to inhibitÂ prostaglandin synthesis, there is an increased incidence of dystocia and delayed parturitionÂ corresponding to a human equivalent dose approximately similar to the maximum recommended clinicalÂ dose (based on bioavailability and body surface area comparison). The effects of VoltarenÂ® Gel onÂ labor and delivery in pregnant women are unknown.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_854913b6-f99b-4877-970e-d2f0ea6d0ec0"></a><a name="section-7.3"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether diclofenac is excreted in human milk; however, studies in animals detectedÂ diclofenac in the milk after oral administration. Because many drugs are excreted in human milk andÂ because of the potential for serious adverse reactions in nursing infants from VoltarenÂ® Gel a decisionÂ should be made whether to discontinue nursing or to discontinue the drug, taking into account theÂ importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_b7ef260c-9ed4-40bf-8f95-f512b8ac96ef"></a><a name="section-7.4"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_3f8be6ec-db6f-4401-84bb-dad85bec341d"></a><a name="section-7.5"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Of the total number of subjects treated with VoltarenÂ® Gel in clinical studies, 498 were 65 years of ageÂ and over. No overall differences in effectiveness or safety were observed between these subjects andÂ younger subjects, but greater sensitivity to the effect of NSAIDs in some older individuals cannot beÂ ruled out.</p>
<p>Diclofenac, as with any NSAID, is known to be substantially excreted by the kidney, and the risk ofÂ toxic reactions to VoltarenÂ® Gel may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. BecauseÂ elderly patients are more likely to have decreased renal function, care should be taken when usingÂ VoltarenÂ® Gel in the elderly, and it may be useful to monitor renal function.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_fff5003a-fbce-447c-9556-204a7802ff0c"></a><a name="section-8"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">There has been no experience of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with VoltarenÂ® Gel.</p>
<p>No events of accidental ingestion have been reported with Voltaren<span class="Bold">Â® </span>Gel. Effects similar to those observedÂ after an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of diclofenac tablets can be expected if substantial amounts of VoltarenÂ® Gel are ingested.Â Symptoms following acute oral NSAID <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> are usually limited to <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>,Â <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">epigastric pain</span>, which are generally reversible with supportive care. Gastrointestinal bleedingÂ can occur. <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span>, <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, and <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> may occur. AnaphylactoidÂ reactions have been reported with therapeutic ingestion of NSAIDs, and may occur after an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.</p>
<p>In the event of oral ingestion resulting in significant systemic side effects, it is recommended that theÂ stomach be emptied by <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> or lavage. Forced <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> may theoretically be beneficial because theÂ drug is excreted in the urine. The effect of dialysis or hemoperfusion in the elimination of diclofenac (99%Â protein-bound) remains unproven. In addition to supportive measures, the use of oral activated charcoalÂ may help to reduce the absorption of diclofenac. Supportive and symptomatic treatment should be given forÂ complications such as <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, <span class="product-label-link" type="condition" conceptid="4318531" conceptname="Gastrointestinal irritation">gastrointestinal irritation</span>, and <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>.Â </p>
<p>For additional information about <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> treatment, call a poison control center (1-800-222-1222).</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_a3ba4a65-c0a9-4543-b2d4-ad93a7ae13ca"></a><a name="section-9"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">VoltarenÂ® Gel (diclofenac sodium topical gel) is a nonsteroidal anti-inflammatory drug (NSAID) for topicalÂ use only. It contains the active ingredient, diclofenac sodium, in an opaque, white gel base. DiclofenacÂ sodium is a white to slightly yellow crystalline powder. Diclofenac sodium is a benzeneâ€“acetic acidÂ derivative. The chemical name is 2-[(2,6-dichlorophenyl)amino]benzeneacetic acid, monosodium salt. TheÂ molecular weight is 318.14. Its molecular formula is C<span class="Sub">14</span>H<span class="Sub">10</span>C<span class="Sub">12</span>NNaO<span class="Sub">2</span>. It has the following structuralÂ formula:</p>
<div class="Figure">
<a name="id852"></a><img alt="ChemStruc" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2280a305-34bd-4f9c-8f31-d6bb6fad90d5&amp;name=2280a305-34bd-4f9c-8f31-d6bb6fad90d5-01.jpg">
</div>
<p>VoltarenÂ® Gel also contains carbomer homopolymer Type C, cocoyl caprylocaprate, fragrance, isopropylÂ alcohol, mineral oil, polyoxyl 20 cetostearyl ether, propylene glycol, purified water, and strong ammoniaÂ solution.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_43474af3-5d1f-4187-895e-642bf42eb4df"></a><a name="section-10"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_id_bdac5d17-e285-45a5-8979-52695860cae1"></a><a name="section-10.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">The mechanism of action of diclofenac is similar to that of other nonsteroidal anti-inflammatory drugs.Â Diclofenac inhibits the enzyme, cyclooxygenase (COX), an early component of the arachidonic acidÂ cascade, resulting in the reduced formation of prostaglandins, thromboxanes and prostacylin. It is notÂ completely understood how reduced synthesis of these compounds results in therapeutic efficacy.Â </p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="i4i_pharmacodynamics_id_d459bd3c-6703-401d-81ef-306e5b105989"></a><a name="section-10.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">Diclofenac, the active component of VoltarenÂ® Gel has anti-inflammatory, anti-nociception, and antipyreticÂ effects.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_810ab500-4e0e-414f-b5d8-04ea5541bdc3"></a><a name="section-10.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">The pharmacokinetics of VoltarenÂ® Gel were assessed in healthy volunteers following repeatedÂ applications during 7 days of VoltarenÂ® Gel to 1 knee (4 x 4 g per day) or to 2 knees and 2 hands (4 xÂ 12 g per day) versus the recommended oral dose of diclofenac sodium for the treatment ofÂ <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span> (3 x 50 mg per day). A summary of the pharmacokinetic parameters is presented inÂ Table 2.</p>
<a name="_Refid_fdce4412-b38a-489d-9735-ca2b17208"></a><table>
<caption><span>Table 2. Pharmacokinetic Parameters and Comparison of Voltaren<span class="Sup">Â®</span>Â Gel to Oral Diclofenac Sodium Tablets After Repeated Administration</span></caption>
<col width="29%">
<col width="25%">
<col width="19%">
<col width="28%">
<tbody class="Headless">
<tr class="First">
<td class="Rrule Toprule" valign="top"><p class="First"><span class="Bold">Treatment</span></p></td>
<td class="Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">C<span class="Sub">max</span> (ng/mL)</span><br><span class="Bold">Mean Â± SD</span><br><span class="Bold">% of Oral (CI)</span></p></td>
<td class="Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">t<span class="Sub">max</span> (hr)</span><br><span class="Bold">Median (range)</span></p></td>
<td class="Toprule" align="center" valign="top"><p class="First"><span class="Bold">AUC<span class="Sub">0-24</span> (ngâ€¢h/mL)</span><br><span class="Bold">Mean Â± SD</span><br><span class="Bold">% of Oral (CI)</span></p></td>
</tr>
<tr>
<td class="Rrule" valign="top"><p class="First">Voltaren<span class="Sup">Â®</span>Â Gel <br>4 x 4 g per day <br>(=160 mg diclofenac sodium per day)</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">15Â± 7.3<br>0.6% (0.5-0.7)</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">14 (0-24)</p></td>
<td align="center" valign="top"><p class="First">233 Â± 128<br>5.8% <br>(5-6.7)</p></td>
</tr>
<tr>
<td class="Rrule" valign="top"><p class="First">Voltaren<span class="Sup">Â®</span>Â Gel <br>4 x 12 g per day <br>(=480 mg diclofenac sodium per day)</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">53.8 Â± 32<br>2.2% <br>(1.9-2.6)</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">10 (0-24)</p></td>
<td align="center" valign="top"><p class="First">807 Â± 478<br>19.7% <br>(17-22.8)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Rrule" valign="top"><p class="First">Diclofenac sodium tablets, orally<br>3 x 50 mg<span class="Bold">Â </span>per day <br>(=150 mg diclofenac sodium per day)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">2270 Â± 778<br>100%</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">6.5 (1-14)</p></td>
<td class="Botrule" align="center" valign="top"><p class="First">3890 Â± 1710<br>100%</p></td>
</tr>
</tbody>
</table>
<p>Â Â Â Â Â  C<span class="Sub">max</span> = maximum plasma concentration; t<span class="Sub">max</span> = time of C<span class="Sub">max</span>;<span class="Sub">Â </span>AUC<span class="Sub">0-24</span> = area </p>
<p>Â Â Â Â Â  under the concentration-time curve; SD = standard deviation; CI = confidence interval.</p>
<p>Systemic exposure (area under the concentration-time curve) and maximum plasma concentrations ofÂ diclofenac are significantly lower with VoltarenÂ® Gel than with comparable oral treatment of diclofenacÂ sodium.</p>
<p>Systemic exposure with recommended use of VoltarenÂ® Gel (4 x 4 g per day applied to 1 knee) is onÂ average 17 times lower than with oral treatment. (Basis: treatment with VoltarenÂ® Gel of 1 knee, 4Â times a day versus 50 mg, 3 times a day of oral diclofenac tablets). The amount of diclofenac sodiumÂ that is systemically absorbed from VoltarenÂ® Gel is on average 6% of the systemic exposure from anÂ oral form of diclofenac sodium.</p>
<p>The average peak plasma concentration with recommended use of VoltarenÂ® Gel (4 x 4 g per dayÂ applied to 1 knee) is 158 times lower than with the oral treatment.Â </p>
<p>The pharmacokinetics of VoltarenÂ® Gel has been tested under conditions of moderate heat (applicationÂ of a heat patch for 15 minutes prior to gel application) and of moderate exercise (first gel applicationÂ followed by a 20-minute treadmill exercise). No clinically relevant differences of systemic absorptionÂ and of tolerability were found between applications of VoltarenÂ® Gel (4 x 4 g per day on 1 knee) withÂ and under the conditions tested. However, the pharmacokinetics of VoltarenÂ® Gel were not tested underÂ the condition of heat application following gel application. Therefore, concurrent use of VoltarenÂ® GelÂ and heat is not recommended.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="i4i_nonclinical_toxicology_id_914ebabf-5d76-408d-9d8d-69dc0570f3a2"></a><a name="section-11"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_8e8b1d83-1940-437e-aa59-ad8ad83dde5e"></a><a name="section-11.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Carcinogenicity studies in mice and rats administered diclofenac sodium as a dietary constituent forÂ 2 years at does up to 2 mg/kg/day resulted in no significant increases in tumor incidenceÂ corresponding to a human equivalent dose approximately 0.5- and 1-fold (mouse and rat,Â respectively) of the maximum human topical dose of VoltarenÂ® Gel (based on bioavailability andÂ body surface area comparison).Â </p>
<p>In a dermal carcinogenicity study conducted in albino mice, daily topical applications of a diclofenacÂ sodium gel product for two years at concentrations up to 0.035% diclofenac sodium (a 29-fold lowerÂ diclofenac sodium concentration than present in VoltarenÂ® Gel) did not increase neoplasmÂ incidence.</p>
<p>In a photococarcinogenicity study conducted in hairless mice, topical application of a diclofenacÂ sodium gel product at doses up to 0.035% diclofenac sodium (a 29-fold lower diclofenac sodiumÂ concentration than present in VoltarenÂ® Gel) resulted in an earlier median time of onset of tumors.Â </p>
<p>Diclofenac was not mutagenic or clastogenic in a battery of genotoxicity tests that included theÂ bacterial reverse mutation assay, <span class="Italics">in vitro </span>mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> point mutation assay, chromosomalÂ aberration studies in Chinese hamster ovarian cells <span class="Italics">in vitro</span>, and <span class="Italics">in vivo </span>rat chromosomal aberrationÂ assay of bone marrow cells.</p>
<p>Diclofenac did not affect male or female fertility in rats at doses up to 4 mg/kg/day which inducedÂ toxicity, corresponding to a human equivalent dose approximately 2-fold greater than the maximumÂ human topical dose of VoltarenÂ® Gel (based on bioavailability and body surface area comparison).Â </p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_90f71699-ab69-4757-8a3d-1ebb25c04256"></a><a name="section-12"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_66380812-140c-45cd-85da-6616ce0195b4"></a><a name="section-12.1"></a><p></p>
<h2>14.1 Pivotal Studies in <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">Osteoarthritis</span> of the Superficial Joints of the Extremities</h2>
<p class="First">Study 1 evaluated the efficacy of VoltarenÂ® Gel for the treatment of <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span> of the knee in aÂ 12-week, randomized, double-blind, multicenter, placebo-controlled, parallel-group trial. VoltarenÂ®Â Gel was administered at a dose of 4 g, 4 times daily, on 1 knee (16 g per day). <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> as assessed byÂ the patients at Week 12 using the WOMAC (Western Ontario and McMaster UniversitiesÂ <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">Osteoarthritis</span> Index) <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> Subindex was lower in the VoltarenÂ® Gel group than the placebo group.</p>
<p>Study 2 evaluated the efficacy of VoltarenÂ® Gel for the treatment of <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span> in subjects withÂ <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span> of the hand in an 8-week, randomized, double-blind, multicenter, placebo-controlled,Â parallel-group study. VoltarenÂ® Gel was administered at a dose of 2 g per hand, 4 times daily, onÂ both hands (16 g per day). <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> in the target hand as assessed by the patients at Weeks 4 and 6 on aÂ visual analog scale from 0 to 100 was lower in the VoltarenÂ® Gel group than the placebo group.</p>
<a name="_Refid_74ad4bf9-67ff-405a-94b9-311dbc7a4"></a><table>
<caption><span>Table 3. Efficacy outcomes of Voltaren<span class="Sup">Â®</span>Â Gel in Studies 1 and 2</span></caption>
<col width="24%">
<col width="17%">
<col width="16%">
<col width="19%">
<col width="25%">
<tbody class="Headless">
<tr class="First">
<td class="Rrule Toprule" valign="top"></td>
<td class="Rrule Toprule" valign="top"></td>
<td class="Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Voltaren<span class="Sup">Â®</span>Â Gel</span></p></td>
<td class="Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Placebo (Vehicle)</span></p></td>
<td class="Toprule" align="center" valign="top"><p class="First"><span class="Bold">Adjusted Difference (Placebo - Voltaren<span class="Sup">Â®</span>Â Gel )</span></p></td>
</tr>
<tr>
<td class="Rrule" valign="top"><p class="First"><span class="Bold">Study 1 (Knee)</span><br><span class="Bold">WOMAC <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> <span class="Sup">* # </span></span><br><span class="Bold">at Week 12</span></p></td>
<td class="Rrule" valign="top"><p class="First">Sample Size</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">127</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">119</p></td>
<td valign="top"></td>
</tr>
<tr>
<td class="Rrule" valign="top"></td>
<td class="Rrule" valign="top"><p class="First">Mean outcome</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">28</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">37</p></td>
<td align="center" valign="top"><p class="First"><span class="Bold">âˆ† = 7<span class="Sup">â€ </span></span></p></td>
</tr>
<tr>
<td class="Rrule" valign="top"></td>
<td class="Rrule" valign="top"><p class="First">95% confidence interval</p></td>
<td class="Rrule" valign="top"></td>
<td class="Rrule" valign="top"></td>
<td align="center" valign="top"><p class="First"><span class="Bold">(1, 12)</span></p></td>
</tr>
<tr>
<td class="Rrule" valign="top"><p class="First"><span class="Bold">Study 2 (Hand)</span><br><span class="Bold"><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> Intensity <span class="Sup">#</span></span><br><span class="Bold">at Week 4</span></p></td>
<td class="Rrule" valign="top"><p class="First">Sample size</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">198</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">187</p></td>
<td valign="top"></td>
</tr>
<tr>
<td class="Rrule" valign="top"></td>
<td class="Rrule" valign="top"><p class="First">Mean outcome</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">43</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">50</p></td>
<td align="center" valign="top"><p class="First"><span class="Bold">âˆ† = 7 <span class="Sup">â€ â€ </span></span></p></td>
</tr>
<tr>
<td class="Rrule" valign="top"></td>
<td class="Rrule" valign="top"><p class="First"> 95% confidence interval</p></td>
<td class="Rrule" valign="top"></td>
<td class="Rrule" valign="top"></td>
<td align="center" valign="top"><p class="First"><span class="Bold">(2, 12)</span></p></td>
</tr>
<tr>
<td class="Rrule" valign="top"><p class="First"><span class="Bold">Study 2 (Hand)</span><br><span class="Bold"><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> Intensity <span class="Sup">#</span></span><br><span class="Bold">at Week 6</span><br></p></td>
<td class="Rrule" valign="top"><p class="First">Sample size</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">198</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">187</p></td>
<td valign="top"></td>
</tr>
<tr>
<td class="Rrule" valign="top"></td>
<td class="Rrule" valign="top"><p class="First">Mean outcome</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">40</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">47</p></td>
<td align="center" valign="top"><p class="First">âˆ† = 7 <span class="Sup">â€ â€ </span></p></td>
</tr>
<tr class="Last">
<td class="Botrule Rrule" valign="top"></td>
<td class="Botrule Rrule" valign="top"><p class="First"> 95% confidence interval</p></td>
<td class="Botrule Rrule" valign="top"></td>
<td class="Botrule Rrule" valign="top"></td>
<td class="Botrule" align="center" valign="top"><p class="First">(1, 13)</p></td>
</tr>
</tbody>
</table>
<p>* WOMAC = Western Ontario McMaster <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">Osteoarthritis</span> Index.</p>
<p># Scale from 0 (best) to 100 (worst), </p>
<p>â€  Difference is adjusted using an analysis of covariance (ANCOVA) model with main effects of treatment and center and baseline covariate.</p>
<p>â€ â€  Difference is adjusted using an analysis of covariance (ANCOVA) model with main effects of treatment, center, indicator for <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the CMC-1 joint, and baseline as a covariate, and the treatment-by-CMC-1 indicator interaction. Difference is weighted by size of CMC-1 strata</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_b96d002e-6c44-4a8b-933c-367748d4104d"></a><a name="section-13"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">VoltarenÂ® Gel is available in tubes containing 100 g of the topical gel in each tube. Physician samples areÂ packaged in 20 g tubes. Each tube contains diclofenac sodium in a gel base (10 mg of diclofenac sodiumÂ per gram of gel or 1%).</p>
<p>Â Â Â Â Â  20 gram tube (physicianâ€™s sample)Â Â Â Â Â Â Â Â Â Â                  NDC 63481-684-83</p>
<p>Â Â Â Â Â  100 gram tubeÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â                                        NDC 63481-684-47</p>
<p>      3 Carton (3 Tubes containing 100 gram each)          NDC 63481-684-03</p>
<p>      5 Carton (5 Tubes containing 100 gram each)          NDC 63481-684-05</p>
<p>Â Â Â Â Â </p>
<p>Â Â Â Â Â <span class="Bold">Storage</span></p>
<p>Store at 25Â°C (77Â°F); excursions permitted to 15-30Â°C (59-86Â°F) [See USP Controlled RoomÂ Temperature]Â </p>
<p>Keep from freezing.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_d0f85046-57a4-45fc-8ebb-384503d179c9"></a><a name="section-14"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">Â Â Â Â Â <span class="Bold">Also See  Section 18 Medical Guide Below.</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_cf648538-faa8-4e6b-9a6b-a91842e496b7"></a><a name="section-14.1"></a><p></p>
<h2>17.1 Medication Guide</h2>
<p class="First">Patients should be informed of the following information before initiating therapy with an NSAIDÂ and periodically during the course of ongoing therapy. Patients should be informed of theÂ availability of a Medication Guide for Non-Steroidal Anti-inflammatory Drugs (NSAIDs), and theyÂ should be instructed to read the Medication Guide prior to using VoltarenÂ® Gel.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_23016729-16af-4273-90ad-ac700975092f"></a><a name="section-14.2"></a><p></p>
<h2>17.2 Cardiovascular effects</h2>
<p class="First">VoltarenÂ® Gel, like other NSAIDs, may cause serious CV side effects, such as MI or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, whichÂ may result in hospitalization and even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Although serious CV events can occur without warningÂ symptoms, patients should be alert for the signs and symptoms of <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>,Â <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, slurring of speech, and should ask for medical advice when observing any indicative signÂ or symptoms. Patients should be apprised of the importance of this follow-up <span class="Italics">[see Warnings andÂ Precautions (5.1)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2e68acad-d54c-4b90-b879-a7988d7505e6"></a><a name="section-14.3"></a><p></p>
<h2>17.3 Gastrointestinal effects</h2>
<p class="First">VoltarenÂ® Gel, like other NSAIDs, can cause GI <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> and, rarely, more serious GI sideÂ effects, such as <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, which may result in hospitalization and even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. AlthoughÂ serious GI tract ulcerations and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> can occur without warning symptoms, patients should beÂ alert for the signs and symptoms of ulcerations and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, and should ask for medical adviceÂ when observing any indicative sign or symptoms including <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">epigastric pain</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="193809" conceptname="Melena due to gastrointestinal hemorrhage">melena</span>, andÂ <span class="product-label-link" type="condition" conceptid="26727" conceptname="Hematemesis">hematemesis</span>. Patients should be apprised of the importance of this follow-up <span class="Italics">[see Warnings andÂ Precautions (5.2)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d4f99fc5-24b3-4faf-9039-8f1109dc0cb5"></a><a name="section-14.4"></a><p></p>
<h2>17.4 Hepatotoxicity</h2>
<p class="First">Patients should be informed of the warning signs and symptoms of hepatotoxicity (e.g., <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>,Â <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, right upper quadrant <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, and â€œflu-likeâ€? symptoms). IfÂ these occur, patients should be instructed to stop therapy with VoltarenÂ® Gel and seek immediateÂ medical therapy <span class="Italics">[see Warnings and Precautions (5.3)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_99a604e5-6e2f-4b5a-81ab-825d1e3317c3"></a><a name="section-14.5"></a><p></p>
<h2>17.5 Adverse <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">Skin Reactions</span></h2>
<p class="First">VoltarenÂ® Gel, like other NSAIDs, can cause serious skin side effects such as <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>,Â SJS, and TEN, which may result in hospitalizations and even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Although serious skin reactionsÂ may occur without warning, patients should be alert for the signs and symptoms of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> andÂ <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, or other signs of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> such as <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, and should ask for medical adviceÂ when observing any indicative signs or symptoms <span class="Italics">[see Warnings and Precautions (5.8)].</span></p>
<p>Patients should be advised to stop VoltarenÂ® Gel immediately if they develop any type of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> andÂ contact their physicians as soon as possible.</p>
<p>Patients should be instructed not to apply VoltarenÂ® Gel to open skin <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wounds</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>,Â <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammations</span>, or <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>, as it may affect absorption and tolerability of the drug.</p>
<p>Patients should be instructed to avoid concomitant use of VoltarenÂ® Gel with other topical products,Â including sunscreens, cosmetics lotions, moisturizers, insect repellants, on the treated skin site.Â Concomitant use may result in <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> or change the absorption of VoltarenÂ® Gel.</p>
<p>Patients should be instructed to minimize or avoid exposure of treated areas to natural or artificialÂ sunlight.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6ff04795-93e2-4af8-a3a9-0814afde475f"></a><a name="section-14.6"></a><p></p>
<h2>17.6 <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight gain</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span></h2>
<p class="First">Patients should promptly report to their physicians signs or symptoms of unexplained <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> orÂ <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> following treatment with VoltarenÂ® Gel <span class="Italics">[see Warnings and Precautions (5.5)]. </span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ea68ca67-2a0f-430a-b676-359a556966a1"></a><a name="section-14.7"></a><p></p>
<h2>17.7 <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid reactions</span></h2>
<p class="First">Patients should be informed of the signs of an <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reaction</span> (e.g., <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">difficulty breathing</span>,Â <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the face or throat). If these occur, patients should be instructed to seek immediateÂ emergency help <span class="Italics">[see Warnings and Precautions (5.7)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_fc1e5f7e-974a-4da8-b25f-c733cdb17232"></a><a name="section-14.8"></a><p></p>
<h2>17.8 Effects during pregnancy</h2>
<p class="First">In late pregnancy, as with other NSAIDs, VoltarenÂ® Gel should be avoided because it will causeÂ premature closure of the ductus arteriosus <span class="Italics">[see Warnings and Precautions (5.9)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_349225a1-80af-41f7-9437-a7c5294cabdc"></a><a name="section-14.9"></a><p></p>
<h2>17.9 Eye Exposure</h2>
<p class="First">Patients should be instructed to avoid contact of VoltarenÂ® Gel with the eyes and mucosa, althoughÂ not studied, should be avoided. Patients should be advised that if eye contact occurs, they shouldÂ immediately wash out the eye with water or saline and consult a physician if irritation persists forÂ more than an hour.</p>
<p>Comments or Questions?</p>
<p>Call toll-free 1-800-452-0051</p>
<table>
<col width="61%">
<col width="39%">
<tbody class="Headless">
<tr class="First">
<td class="Toprule" valign="top"><p class="First">Marketed by:<br>Endo Pharmaceuticals Inc.<br>Chadds Ford, PA 19317<br>Â Â Â </p></td>
<td class="Toprule" valign="top"></td>
</tr>
<tr>
<td valign="top"><p class="First">Manufactured for:<br>Novartis Consumer Health, Inc.<br>Parsippany, NJ 07054<br>Â Â Â </p></td>
<td valign="top"></td>
</tr>
<tr class="Last">
<td class="Botrule" valign="top"><p class="First">Manufactured by:<br>Novartis Pharma Produktions GmbH<br>Wehr, Germany</p></td>
<td class="Botrule" valign="top"></td>
</tr>
</tbody>
</table>
<p>Â©2009 Novartis Consumer Health, Inc., Parsippany, NJ 07054. All Trademarks owned and licensed by Novartis AG</p>
<p>42035D / October 2009</p>
<p>Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â </p>
</div>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="i4i_medguide_id_19227e4f-f911-4171-a503-004472bb02af"></a><a name="section-15"></a><p></p>
<h1>18 MEDICAL GUIDE</h1>
<p class="First"><span class="Bold"><span class="Underline">Medication GuideforNon-steroidal Anti-Inflammatory Drugs (NSAIDs)</span></span></p>
<p><span class="Underline">(See the end of this Medication Guide for a list of prescription NSAID medicines.)</span></p>
<p><span class="Bold">What is the most important information I should know about medicines called Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)?</span></p>
<p><span class="Bold">NSAID medicines may increase the chance of a <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span> or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> that can lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. </span>ThisÂ chance increases:</p>
<dl>
<dt>â€¢</dt>
<dd>with longer use of NSAID medicines<br>
</dd>
<dt>â€¢</dt>
<dd>in people who have heart disease</dd>
</dl>
<p><span class="Bold">NSAID medicines should never be used right before or after a heart surgery called a â€œcoronaryÂ artery bypass graft (CABG).â€?</span></p>
<p><span class="Bold">NSAID medicines can cause <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in the stomach and intestines at any time duringÂ treatment. <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">Ulcers</span> and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>:</span></p>
<dl>
<dt>â€¢</dt>
<dd>can happen without warning symptoms<br>
</dd>
<dt>â€¢</dt>
<dd>may cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span></dd>
</dl>
<p>Â Â Â Â Â <span class="Bold">The chance of a person getting an <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> increases with:</span></p>
<dl>
<dt>â€¢</dt>
<dd>taking medicines called â€œcorticosteroidsâ€? and â€œanticoagulantsâ€?<br>
</dd>
<dt>â€¢</dt>
<dd>longer use<br>
</dd>
<dt>â€¢</dt>
<dd>smoking<br>
</dd>
<dt>â€¢</dt>
<dd>drinking alcohol<br>
</dd>
<dt>â€¢</dt>
<dd>older age<br>
</dd>
<dt>â€¢</dt>
<dd>having poor health</dd>
</dl>
<p><span class="Bold">NSAID medicines should only be used:</span></p>
<dl>
<dt>â€¢</dt>
<dd>exactly as prescribed<br>
</dd>
<dt>â€¢</dt>
<dd>at the lowest dose possible for your treatment<br>
</dd>
<dt>â€¢</dt>
<dd>for the shortest time needed</dd>
</dl>
<p>Â </p>
<p><span class="Bold">What are Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)?</span></p>
<p>NSAID medicines are used to treat <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, and heat (<span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>) from medical conditionsÂ such as:</p>
<dl>
<dt>â€¢</dt>
<dd>different types of <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span><br>
</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">menstrual cramps</span> and other types of short-term <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></dd>
</dl>
<p>Â </p>
<p><span class="Bold">Who should not take a Non-Steroidal Anti-Inflammatory Drug (NSAID)?</span></p>
<p><span class="Bold">Do not take an NSAID medicine:</span></p>
<dl>
<dt>â€¢</dt>
<dd>if you had an <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> attack, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>, or other <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> with aspirin or any other NSAIDÂ medicine<br>
</dd>
<dt>â€¢</dt>
<dd>for <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> right before or after heart bypass surgery</dd>
</dl>
<p>Â </p>
<p><span class="Bold">Tell your healthcare provider:</span></p>
<dl>
<dt>â€¢</dt>
<dd>about all of your medical conditions.<br>
</dd>
<dt>â€¢</dt>
<dd>about all of the medicines you take. NSAIDs and some other medicines can interact with each otherÂ and cause serious side effects. <span class="Bold">Keep a list of your medicines to show to your healthcare providerÂ and pharmacist.</span>
</dd>
<dt>â€¢</dt>
<dd>if you are pregnant. <span class="Bold">NSAID medicines should not be used by pregnant women late in theirÂ pregnancy.</span><br>
</dd>
<dt>â€¢</dt>
<dd>if you are breastfeeding. <span class="Bold">Talk to your doctor.</span>
</dd>
</dl>
<p>Â </p>
<p><span class="Bold">What are the possible side effects of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)?</span></p>
<table>
<col width="58%">
<col width="42%">
<tbody class="Headless"><tr class="First Last">
<td class="Botrule Rrule Toprule" valign="top">
<p class="First"><span class="Bold">Serious side effects include: </span></p>
<dl>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span> <br>
</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> <br>
</dd>
<dt>â€¢</dt>
<dd>high blood pressure <br>
</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> from body <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> (<span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>) <br>
</dd>
<dt>â€¢</dt>
<dd>kidney problems including <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">kidney failure</span> <br>
</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> and <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> in the stomach and intestine <br>
</dd>
<dt>â€¢</dt>
<dd>low red blood cells (<span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>) <br>
</dd>
<dt>â€¢</dt>
<dd>life-threatening <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> <br>
</dd>
<dt>â€¢</dt>
<dd>life-threatening <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> <br>
</dd>
<dt>â€¢</dt>
<dd>liver problems including <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span> <br>
</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> attacks in people who have <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> </dd>
</dl>
</td>
<td class="Botrule Toprule" valign="top">
<p class="First"><span class="Bold">Other side effects include:</span><br></p>
<dl>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span> <br>
</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> <br>
</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> <br>
</dd>
<dt>â€¢</dt>
<dd>gas <br>
</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span> <br>
</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> <br>
</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> <br>
</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> </dd>
</dl>
</td>
</tr></tbody>
</table>
<p><span class="Bold">Get emergency help right away if you have any of the following symptoms:</span></p>
<table>
<col width="55%">
<col width="45%">
<tbody class="Headless"><tr class="First Last">
<td class="Botrule Toprule" valign="top"><dl>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> or trouble breathing <br>
</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> <br>
</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> in one part or side of your body </dd>
</dl></td>
<td class="Botrule Toprule" valign="top"><dl>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">slurred speech</span> <br>
</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the face or throat </dd>
</dl></td>
</tr></tbody>
</table>
<p><span class="Bold">Stop your NSAID medicine and call your healthcare provider right away if you have any of the followingÂ symptoms:</span></p>
<table>
<col width="55%">
<col width="45%">
<tbody class="Headless"><tr class="First Last">
<td class="Botrule Toprule" valign="top"><dl>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> <br>
</dd>
<dt>â€¢</dt>
<dd>more tired or weaker than usual <br>
</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span> <br>
</dd>
<dt>â€¢</dt>
<dd>your skin or eyes look yellow <br>
</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span> <br>
</dd>
<dt>â€¢</dt>
<dd>flu-like symptoms <br>
</dd>
<dt>â€¢</dt>
<dd>vomit blood </dd>
</dl></td>
<td class="Botrule Toprule" valign="top"><dl>
<dt>â€¢</dt>
<dd>there is blood in your bowel movement or it is black and sticky like tar <br>
</dd>
<dt>â€¢</dt>
<dd>unusual <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> <br>
</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> or <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> with <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> <br>
</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the arms and legs, hands and feet </dd>
</dl></td>
</tr></tbody>
</table>
<p>These are not all the side effects with NSAID medicines. Talk to your healthcare provider or pharmacist forÂ more information about NSAID medicines.</p>
<p><span class="Bold">Other information about Non-Steroidal Anti-Inflammatory Drugs (NSAIDs):</span></p>
<dl>
<dt>â€¢</dt>
<dd>Aspirin is an NSAID medicine but it does not increase the chance of a <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>. Aspirin can causeÂ <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in the brain, stomach, and intestines. Aspirin can also cause <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> in the stomach and intestines.<br>
</dd>
<dt>â€¢</dt>
<dd>Some of these NSAID medicines are sold in lower doses without a prescription (over-the-counter). Talk toÂ your healthcare provider before using over-the-counter NSAIDs for more than 10 days.</dd>
</dl>
<p><span class="Underline">Â </span></p>
<p><span class="Bold"><span class="Underline">NSAID medicines that need a prescription</span></span></p>
<table>
<col width="30%">
<col width="70%">
<tbody class="Headless">
<tr class="First">
<td class="Rrule Toprule" valign="top"><p class="First"><span class="Bold">Generic Name </span></p></td>
<td class="Toprule" valign="top"><p class="First"><span class="Bold">Tradename</span></p></td>
</tr>
<tr>
<td class="Rrule" valign="top"><p class="First">Celecoxib</p></td>
<td valign="top"><p class="First">Celebrex<span class="Sup">Â®</span></p></td>
</tr>
<tr>
<td class="Rrule" valign="top"><p class="First">Diclofenac</p></td>
<td valign="top"><p class="First">Cataflam<span class="Sup">Â®</span>, Voltaren<span class="Sup">Â®</span>, Arthrotecâ„¢ (combined with misoprostol)</p></td>
</tr>
<tr>
<td class="Rrule" valign="top"><p class="First">Diflunisal</p></td>
<td valign="top"><p class="First">Dolobid<span class="Sup">Â®</span></p></td>
</tr>
<tr>
<td class="Rrule" valign="top"><p class="First">Etodolac</p></td>
<td valign="top"><p class="First">Lodine<span class="Sup">Â®</span>, Lodine<span class="Sup">Â®</span>XL</p></td>
</tr>
<tr>
<td class="Rrule" valign="top"><p class="First">Fenoprofen</p></td>
<td valign="top"><p class="First">Nalfon<span class="Sup">Â®</span>, Nalfon<span class="Sup">Â®</span>200</p></td>
</tr>
<tr>
<td class="Rrule" valign="top"><p class="First">Flurbirofen</p></td>
<td valign="top"><p class="First">Ansaid<span class="Sup">Â®</span></p></td>
</tr>
<tr>
<td class="Rrule" valign="top"><p class="First">Ibuprofen</p></td>
<td valign="top"><p class="First">Motrin<span class="Sup">Â®</span>, Tab-Profen<span class="Sup">Â®</span>, Vicoprofen<span class="Sup">Â®*</span> (combined with hydrocodone), Combunoxâ„¢ (combined with oxycodone)</p></td>
</tr>
<tr>
<td class="Rrule" valign="top"><p class="First">Indomethacin</p></td>
<td valign="top"><p class="First">Indocin<span class="Sup">Â®</span>, Indocin<span class="Sup">Â®</span>SR, Indo-Lemmonâ„¢, Indomethaganâ„¢</p></td>
</tr>
<tr>
<td class="Rrule" valign="top"><p class="First">Ketoprofen</p></td>
<td valign="top"><p class="First">Oruvail<span class="Sup">Â®</span></p></td>
</tr>
<tr>
<td class="Rrule" valign="top"><p class="First">Ketorolac</p></td>
<td valign="top"><p class="First">Toradol<span class="Sup">Â®</span></p></td>
</tr>
<tr>
<td class="Rrule" valign="top"><p class="First">MefenamicÂ Acid</p></td>
<td valign="top"><p class="First">Ponstel<span class="Sup">Â®</span></p></td>
</tr>
<tr>
<td class="Rrule" valign="top"><p class="First">Meloxicam</p></td>
<td valign="top"><p class="First">Mobic<span class="Sup">Â®</span></p></td>
</tr>
<tr>
<td class="Rrule" valign="top"><p class="First">Nabumetone</p></td>
<td valign="top"><p class="First">Relafen<span class="Sup">Â®</span></p></td>
</tr>
<tr>
<td class="Rrule" valign="top"><p class="First">Naproxen</p></td>
<td valign="top"><p class="First">Naprosyn<span class="Sup">Â®</span>, Anaprox<span class="Sup">Â®</span>, Anaprox<span class="Sup">Â®</span>DS, EC-Naprosyn<span class="Sup">Â®</span>, Naprelan<span class="Sup">Â®</span>, Naprapac<span class="Sup">Â®</span> (copackaged with lansoprazole)</p></td>
</tr>
<tr>
<td class="Rrule" valign="top"><p class="First">Oxaprozin</p></td>
<td valign="top"><p class="First">Daypro<span class="Sup">Â®</span></p></td>
</tr>
<tr>
<td class="Rrule" valign="top"><p class="First">Piroxicam</p></td>
<td valign="top"><p class="First">Feldene<span class="Sup">Â®</span></p></td>
</tr>
<tr>
<td class="Rrule" valign="top"><p class="First">Sulindac</p></td>
<td valign="top"><p class="First">Clinoril<span class="Sup">Â®</span></p></td>
</tr>
<tr class="Last">
<td class="Botrule Rrule" valign="top"><p class="First">Tolmetin</p></td>
<td class="Botrule" valign="top"><p class="First">Tolectin<span class="Sup">Â®</span>, Tolectin DS<span class="Sup">Â®</span>, Tolectin<span class="Sup">Â®</span>600</p></td>
</tr>
</tbody>
</table>
<p>*Vicoprofen contains the same dose of ibuprofen as over-the-counter (OTC) NSAID, and is usually used forÂ less than 10 days to treat <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. The OTC NSAID label warns that long term continuous use may increase theÂ risk of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span> or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>.</p>
<p>This Medication Guide has been approved by the U.S. Food and Drug Administration.Â </p>
<p>Revised: June 2008</p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="i4i_patient_package_insert_id_8f5bc6c8-c09c-40c0-9824-fddf8a90fe62"></a><a name="section-16"></a><p></p>
<h1>19 Patient Package Insert</h1>
<p class="First"><span class="Bold">Patient Instructions for Use</span></p>
<p>Your doctor has prescribed Voltaren<span class="Sup">Â®</span> Gel to help relieve <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span> <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in some of your joints. Voltaren<span class="Sup">Â®</span> Gel may be used to treat <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span> <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>:</p>
<dl>
<dt>â€¢</dt>
<dd>In the arms: hands, wrists and elbows.<br>
</dd>
<dt>â€¢</dt>
<dd>In the legs: feet, ankles and knees.<br>
</dd>
<dt>â€¢</dt>
<dd>Use Voltaren<span class="Sup">Â®</span> Gel exactly how your doctor prescribes it for you. Do not apply Voltaren<span class="Sup">Â®</span> Gel anywhere other than where your doctor tells you to.<br>
</dd>
<dt>â€¢</dt>
<dd><span class="Bold">Do not use more than a total of 32 grams of Voltaren<span class="Sup">Â®</span> Gel each day. This means that if you add up the amount of Voltaren<span class="Sup">Â®</span> Gel as directed by your doctor, it should not be more than 32 grams in one day.</span></dd>
</dl>
<p>The dose for your hands, elbows or wrists is 2 grams of Voltaren<span class="Sup">Â®</span> Gel each time you apply it.</p>
<dl>
<dt>â€¢</dt>
<dd>Apply Voltaren<span class="Sup">Â®</span> Gel 4 times a day (a total of 8 grams each day).<br>
</dd>
<dt>â€¢</dt>
<dd>Do not apply more than 8 grams each day to any one of your affected hands, wrists or elbows</dd>
</dl>
<p>The dose for your knees, ankles or feet is 4 grams of Voltaren<span class="Sup">Â®</span> Gel each time you apply it.</p>
<dl>
<dt>â€¢</dt>
<dd>Apply Voltaren<span class="Sup">Â®</span> Gel 4 times a day (a total of 16 grams each day)<br>
</dd>
<dt>â€¢</dt>
<dd>Do not apply more than 16 grams each day to any one of your affected knees, ankles or feet.</dd>
</dl>
<p>Some examples include:</p>
<dl>
<dt>â€¢</dt>
<dd>If you use 2 grams of Voltaren<span class="Sup">Â®</span> Gel on one hand, 4 times a day, your total dose for one day is 8 grams<br>
</dd>
<dt>â€¢</dt>
<dd>If you use 4 grams of Voltaren<span class="Sup">Â®</span> Gel on one knee, 4 times a day, your total dose for one day is 16 grams.<br>
</dd>
<dt>â€¢</dt>
<dd>Your total dose for one day, treating one hand and one knee, is 8 grams plus 16 grams, which equals 24 grams of Voltaren<span class="Sup">Â®</span> Gel.<br>
</dd>
<dt>â€¢</dt>
<dd>Before you use a new tube of Voltaren<span class="Sup">Â®</span> Gel for the first time, open the foil seal that covers the tube opening by using the spiked top of the cap. Remember to remove the dosing card from the carton.<br>
</dd>
<dt>â€¢</dt>
<dd>Apply Voltaren<span class="Sup">Â®Â Â </span>Gel to clean, <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">dry skin</span> that does not have any cuts, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> or <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rashes</span>.Â <br>
</dd>
<dt>â€¢</dt>
<dd>Do not use heating pads or apply bandages where you have applied Voltaren<span class="Sup">Â®</span> Gel.<br>
</dd>
<dt>â€¢</dt>
<dd>Avoid exposing skin where you apply Voltaren<span class="Sup">Â®</span> Gel to sunlight and artificial light, such as tanning booths.<br>
</dd>
<dt>â€¢</dt>
<dd>Do not use sunscreens, cosmetics, lotions, moisturizers, insect repellants, or other topical medicines on the same skin areas where you have applied Voltaren<span class="Sup">Â®</span> Gel.Â Â <br>
</dd>
<dt>â€¢</dt>
<dd>Do not get Voltaren<span class="Sup">Â®</span> Gel in your eyes, nose or mouth. Voltaren<span class="Sup">Â®</span> Gel is only to be used on your skin (topical use). If you get Voltaren<span class="Sup">Â®</span> Gel in your eyes, rinse your eyes right away with water or saline. Talk with your doctor if <span class="product-label-link" type="condition" conceptid="4049206" conceptname="Burning sensation in eye">eye irritation</span> lasts for more than one hour.</dd>
</dl>
<p>Â </p>
<p><span class="Bold">What to do if you miss a dose:</span></p>
<dl>
<dt>â€¢</dt>
<dd>If you miss a dose of Voltaren<span class="Sup">Â®</span> Gel, continue with your next scheduled dose using the proper amount of Voltaren<span class="Sup">Â®Â </span>Gel. </dd>
<dt>â€¢</dt>
<dd>Do <span class="Underline">not </span>double the dose. <span class="Sup">Â Â Â </span><span class="Underline">Â </span>
</dd>
</dl>
<p>Â </p>
<p><span class="Bold">Applying Voltaren<span class="Sup">Â®</span> Gel to hands, elbows or wrists:</span></p>
<table>
<col width="34%">
<col width="81%">
<tbody class="Headless">
<tr class="First"><td class="Toprule" colspan="2" valign="top"><p class="First">1. The dose for each hand, elbow or wrist is 2 grams of Voltaren<span class="Sup">Â® </span>Gel. </p></td></tr>
<tr><td colspan="2" valign="top"><dl>
<dt>â€¢</dt>
<dd>Apply Voltaren<span class="Sup">Â®</span> GelÂ  4 times a day (a total of 8 grams each day). <br>
</dd>
<dt>â€¢</dt>
<dd>Do not apply more than 8 grams each day to any one of your affected hands, wrists or elbows.</dd>
</dl></td></tr>
<tr><td colspan="2" valign="top"><p class="First">2. To measure the right amount of Voltaren<span class="Sup">Â®</span> Gel, remove one dosing card from the package and place the card on a flat surface so that you can read the print. If the print is backwards, flip dosing card over.Â Â See the picture below.</p></td></tr>
<tr>
<td align="center" valign="top">
<a name="id1693"></a><img alt="Img1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2280a305-34bd-4f9c-8f31-d6bb6fad90d5&amp;name=2280a305-34bd-4f9c-8f31-d6bb6fad90d5-02.jpg">
</td>
<td valign="top"></td>
</tr>
<tr><td colspan="2" valign="top"><p class="First">3. Squeeze Voltaren<span class="Sup">Â®</span>Â Gel onto the dosing card evenly, up to the 2 gram line.Â Make sure the gel covers the entire 2 gram area of the dosing card as shown in the picture below. Put the cap back on the tube of Voltaren<span class="Sup">Â®</span> Gel.</p></td></tr>
<tr>
<td align="center" valign="top">
<a name="id1701"></a><img alt="Img2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2280a305-34bd-4f9c-8f31-d6bb6fad90d5&amp;name=2280a305-34bd-4f9c-8f31-d6bb6fad90d5-03.jpg">
</td>
<td valign="top"></td>
</tr>
<tr><td colspan="2" valign="top"><p class="First">4. Apply the gel to your elbow, wrist, or hand. You can use the dosing card to apply the gel.. The hands should be used to gently rub the gel into the skin. Do not share the dosing card with another person.</p></td></tr>
<tr><td colspan="2" valign="top"><p class="First">Make sure to cover the entire affected elbow, wrist or hand with the gel.Â Remember that the hand includes the palm of your hand, the top of your hand and your fingers.</p></td></tr>
<tr>
<td align="center" valign="top">
<a name="id1710"></a><img alt="Img3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2280a305-34bd-4f9c-8f31-d6bb6fad90d5&amp;name=2280a305-34bd-4f9c-8f31-d6bb6fad90d5-04.jpg"><a name="id1711"></a><img alt="Img4" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2280a305-34bd-4f9c-8f31-d6bb6fad90d5&amp;name=2280a305-34bd-4f9c-8f31-d6bb6fad90d5-05.jpg">
</td>
<td valign="top"></td>
</tr>
<tr><td colspan="2" valign="top"><p class="First">5. After using the dosing card, hold end with fingertips, rinse and dry. Store dosing card until next use. Store out of reach of children.</p></td></tr>
<tr>
<td align="center" valign="top">
<a name="id1717"></a><img alt="Img5" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2280a305-34bd-4f9c-8f31-d6bb6fad90d5&amp;name=2280a305-34bd-4f9c-8f31-d6bb6fad90d5-06.jpg">
</td>
<td valign="top"></td>
</tr>
<tr><td colspan="2" valign="top">
<p class="First">6.Â Â Â Â Â  Do not shower or bathe for at least 1 hour after applying Voltaren<span class="Sup">Â®</span> Gel. Do not wash your treated hand for at least 1 hour after</p>
<p> applying Voltaren<span class="Sup">Â®</span> Gel.Â </p>
</td></tr>
<tr class="Last"><td class="Botrule" colspan="2" valign="top"><p class="First">7.Â Â Â Â Â  Wait 10 minutes before covering the treated skin with gloves or clothing..</p></td></tr>
</tbody>
</table>
<p><span class="Bold">Applying Voltaren<span class="Sup">Â®</span> Gel to knees, ankles, or feet:</span></p>
<table>
<col width="34%">
<col width="21%">
<col width="59%">
<tbody class="Headless">
<tr class="First"><td class="Toprule" colspan="3" valign="top"><p class="First">1. The dose for each knee, ankle or foot is 4 grams of Voltaren<span class="Sup">Â® </span>Gel. </p></td></tr>
<tr><td colspan="3" valign="top"><dl>
<dt>â€¢</dt>
<dd>Apply Voltaren<span class="Sup">Â®</span> Gel 4 times a day (a total 16 grams each day). <br>
</dd>
<dt>â€¢</dt>
<dd>Do not apply more than 16 grams each day to any one of your affected knees, ankles or feet.</dd>
</dl></td></tr>
<tr><td colspan="3" valign="top">
<p class="First">2. To measure the right amount of Voltaren<span class="Sup">Â®</span> Gel, place the dosing card on a flat surface so that you can read the print. If the print is</p>
<p> backwards, flip dosing card over.Â See the picture below.Â </p>
</td></tr>
<tr>
<td align="center" valign="top">
<a name="id1754"></a><img alt="Img6" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2280a305-34bd-4f9c-8f31-d6bb6fad90d5&amp;name=2280a305-34bd-4f9c-8f31-d6bb6fad90d5-07.jpg">
</td>
<td colspan="2" valign="top"></td>
</tr>
<tr><td colspan="3" valign="top"><p class="First">3. Squeeze Voltaren<span class="Sup">Â®</span> Gel onto the dosing card evenly up to the 4 gram line, making sure the gel covers the entire 4 gram area of the dosing card, as shown in the picture below. Put the cap back on the tube of Voltaren<span class="Sup">Â®</span> Gel.</p></td></tr>
<tr>
<td align="center" valign="top">
<a name="id1762"></a><img alt="Img7" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2280a305-34bd-4f9c-8f31-d6bb6fad90d5&amp;name=2280a305-34bd-4f9c-8f31-d6bb6fad90d5-08.jpg">
</td>
<td colspan="2" valign="top"></td>
</tr>
<tr><td colspan="3" valign="top"><p class="First">4. Apply Voltaren<span class="Sup">Â®</span> Gel to foot, ankle or knee and gently rub the gel into the skin. </p></td></tr>
<tr><td colspan="3" valign="top"><dl>
<dt>â€¢</dt>
<dd>You can use the dosing card to apply the gel. <br>
</dd>
<dt>â€¢</dt>
<dd>Make sure to cover the entire foot, ankle or knee area with the gel. </dd>
</dl></td></tr>
<tr><td colspan="3" valign="top"><p class="First">For example, cover the skin above, below, inside and outside the knee cap. Remember that the foot includes the sole of your foot, the top of your foot and your toes. </p></td></tr>
<tr>
<td align="center" valign="top">
<a name="id1777"></a><img alt="Img8" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2280a305-34bd-4f9c-8f31-d6bb6fad90d5&amp;name=2280a305-34bd-4f9c-8f31-d6bb6fad90d5-09.jpg"><a name="id1778"></a><img alt="Img9" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2280a305-34bd-4f9c-8f31-d6bb6fad90d5&amp;name=2280a305-34bd-4f9c-8f31-d6bb6fad90d5-10.jpg">
</td>
<td valign="top"><p class="First">Â Â Â </p></td>
<td valign="top"></td>
</tr>
<tr><td colspan="3" valign="top"><p class="First">5. After using the dosing card, fold the used dosing card in half (application side inside) and throw it away in a safe place out of the reach of children and pets.</p></td></tr>
<tr>
<td align="center" valign="top">
<a name="id1785"></a><img alt="Img10" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2280a305-34bd-4f9c-8f31-d6bb6fad90d5&amp;name=2280a305-34bd-4f9c-8f31-d6bb6fad90d5-11.jpg">
</td>
<td colspan="2" valign="top"></td>
</tr>
<tr><td colspan="3" valign="top"><p class="First">6. Do not shower or bathe for 1 hour after application.<br>7. Wait 10 minutes before covering the treated skin with clothing.</p></td></tr>
<tr class="Last"><td class="Botrule" colspan="3" valign="top"><p class="First">8. Wash your hands after applying Voltaren<span class="Sup">Â®</span> Gel to your foot, ankle or knee.</p></td></tr>
</tbody>
</table>
<p>Store VoltarenÂ® Gel at room temperature, 59Â° F to 86Â°F (15Â°C to 30Â°C).</p>
<p>All registered trademarks in this document are the property of their respective owners.</p>
<p>Comments or Questions?</p>
<p>Call toll-free 1-800-452-0051</p>
<table>
<col width="61%">
<col width="39%">
<tbody class="Headless">
<tr class="First">
<td class="Toprule" valign="top"><p class="First">Marketed by:<br>Endo Pharmaceuticals Inc.<br>Chadds Ford, PA 19317<br>Â Â Â </p></td>
<td class="Toprule" valign="top"></td>
</tr>
<tr>
<td valign="top"><p class="First">Manufactured for:<br>Novartis Consumer Health, Inc.<br>Parsippany, NJ 07054<br>Â Â Â </p></td>
<td valign="top"></td>
</tr>
<tr class="Last">
<td class="Botrule" valign="top"><p class="First">Manufactured by:<br>Novartis Pharma Produktions GmbH<br>Wehr, Germany</p></td>
<td class="Botrule" valign="top"></td>
</tr>
</tbody>
</table>
<p>Â©2009 Novartis Consumer Health, Inc., Parsippany, NJ 07054. All Trademarks owned and licensed by Novartis AG</p>
<p>42035D/ October 2009Â Â Â Â Â Â Â Â Â Â Â Â </p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_cdfbb2c2-2cf0-4939-a841-17faab8a73d9"></a><a name="section-17"></a><p></p>
<h1>Principal Display Panel</h1>
<div class="Figure">
<a name="id1882"></a><img alt="Voltaren Gel" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2280a305-34bd-4f9c-8f31-d6bb6fad90d5&amp;name=2280a305-34bd-4f9c-8f31-d6bb6fad90d5-12.jpg"><p class="MultiMediaCaption">Voltaren Gel </p>
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>VOLTARENÂ 		
					</strong><br><span class="contentTableReg">diclofenac sodium gel</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:58118-0684(NDC:63481-684)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">TOPICAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>DICLOFENAC SODIUM</strong> (DICLOFENAC) </td>
<td class="formItem">DICLOFENAC SODIUM</td>
<td class="formItem">10Â mg Â inÂ 1Â g</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong><span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">AMMONIA</span></strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CARBOMER HOMOPOLYMER TYPE C (ALLYL PENTAERYTHRITOL CROSSLINKED)</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ISOPROPYL ALCOHOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MINERAL OIL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYOXYL 20 CETOSTEARYL ETHER</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:58118-0684-1</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">100 g in 1 TUBE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022122</td>
<td class="formItem">10/17/2007</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Clinical Solutions Wholesale
							(078710347)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant -Â </span>Clinical Solutions Wholesale (078710347)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Clinical Solutions Wholesale</td>
<td class="formItem"></td>
<td class="formItem">078710347</td>
<td class="formItem">RELABEL(58118-0684)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 11/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>2280a305-34bd-4f9c-8f31-d6bb6fad90d5</div>
<div>Set id: 2280a305-34bd-4f9c-8f31-d6bb6fad90d5</div>
<div>Version: 1</div>
<div>Effective Time: 20131114</div>
</div>
</div>Â <div class="DistributorName">Clinical Solutions Wholesale</div></p>
</body></html>
